Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis.
Depletion of glutathione by inhibition of its synthesis by buthionine sulfoximine, an irreversible inhibitor of gamma-glutamylcysteine synthetase, leads to increased sensitivity to (i) irradiation and (ii) oxidative stress. In the present work, an intracellular cysteine delivery system was used to promote glutathione synthesis, and this was found to protect against toxicity. Thus, administration of L-2-oxothiazolidine-4-carboxylate protected against acetaminophen toxicity in mice; the thiazolidine, which is converted to L-cysteine by the enzyme 5-oxo-L-prolinase (present in many animal tissues and in plants) promotes the synthesis of glutathione, which is the actual protectant. The effect of this thiazolidine in increasing the level of glutathione is prevented by administration of buthionine sulfoximine. This thiazolidine may be useful in the treatment of other toxicities and in the treatment of certain diseases. It may also be valuable as a component of amino acid mixtures used in therapy and as a safener in agriculture.
D000082:Acetaminophen / Q000037:antagonists & inhibitors / Q000633:toxicity; D000818:Animals; D003545:Cysteine / Q000008:administration & dosage*; D005978:Glutathione / Q000096:biosynthesis*; D005981:Glutathione Synthase / Q000378:metabolism; D008658:Inactivation, Metabolic; D008099:Liver / Q000378:metabolism; D051379:Mice; D011761:Pyrrolidonecarboxylic Acid; D013844:Thiazoles / Q000627:therapeutic use*; D053778:Thiazolidines
D013844:Thiazoles; D053778:Thiazolidines; D000082:Acetaminophen; D005981:Glutathione Synthase; D005978:Glutathione; D003545:Cysteine; D011761:Pyrrolidonecarboxylic Acid; C029536:2-oxothiazolidine-4-carboxylic acid